Results 81 to 90 of about 1,304 (177)

Prolonged neuromuscular blockade by non-depolarizing neuromuscular blocking agents

JA Clinical Reports, 2019
Michiko Higashi, Takahiro Tamura, Yushi U. Adachi   +2 more
doaj   +1 more source

Erratum: Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents [PDF]

Korean Journal of Anesthesiology, 2017
Yong Beom Kim, Tae-Yun Sung, Hong Seuk Yang   +2 more
doaj   +1 more source

Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor

Background: Nondepolarizing neuromuscular blocking agents (NMBAs) are classic competitive-inhibitors at the muscle nicotinic acetylcholine receptor (nAChR).
Fagerlund, Malin Jonsson
core  

Sedation and Analgesia

, 2017
This chapter on sedation and analgesia provides essential information on how to achieve and monitor the comfort of patients safely in the pediatric intensive care unit. Included is succinct information about dosing, pharmacodynamics, and pharmacokinetics
Lynn D. Martin, Iskra I. Ivanova
core   +1 more source

Effectiveness versus Efficacy of Calabadion and Sugammadex for Nondepolarizing Neuromuscular Blocking Agent Reversal [PDF]

Anesthesiology, 2016
Grace, Lim, Douglas P, Landsittel
openaire   +2 more sources

Evidence-Based Guidelines for Intraoperative Quantitative Neuromuscular Monitoring

Nondepolarizing neuromuscular blocking agents are routinely used medications vital to anesthetic care. When administering neuromuscular blocking agents, monitoring neuromuscular blockade depth and degree of recovery is a standard of nurse anesthesia ...
Graham, Noah
core  

Identification of Residual Neuromuscular Blockade in Post-Surgical Patients

, 2017
Background: Many surgical procedures require administration of nondepolarizing neuromuscular blocking (NDNMB) agents. NDNMBs are typically reversed when surgery ends , allowing function to be restored.
Martin, Nicole, NC DOCKS at East Carolina University   +1 more
core   +1 more source

Sugammadex in patients with Myasthenia Gravis

, 2021
Myasthenia gravis (MG) is an autoimmune disorder caused by a decrease in functional acetylcholine receptors at the neuromuscular junction resulting from their destruction or inactivation by antibodies.
Harrison, Presley
core  

Rocuronium-specific antibodies drive perioperative anaphylaxis but can also function as reversal agents in preclinical models

: Neuromuscular blocking agents (NMBAs) relax skeletal muscles to facilitate surgeries and ease intubation but can lead to adverse reactions, including complications because of postoperative residual neuromuscular blockade (rNMB) and, in rare cases ...
Bay, Sylvie, Ganneau, Christelle, de Chaisemartin, Luc, Haouz, Ahmed, Sokal, Aur\ue9lien, Pecalvel, Cyprien, Chappert, Pascal, Chollet-Martin, Sylvie, Reber, Laurent L., Nicaise-Roland, Pascale, Goff, Odile Richard-Le, Bruhns, Pierre, Lemaitre, Julien, Vandenberghe, Alexis, Iannascoli, Bruno, Pissis, C\ue9dric, Rose, Thierry, Zhu, Qianqian, Derenne, Thomas, Mah\ue9vas, Matthieu, Gouel-Ch\ue9ron, Aur\ue9lie, Godon, Oph\ue9lie, Relouzat, Francis, Le Grand, Roger, Letscher, H\ue9l\ue8ne, Huetz, Fran\ue7ois, Mertens, Christel, Gillis, Caitlin M., Ebo, Didier, Dejoux, Alice, Hunault, Lise, Millot, Ga\uebl A., Wang, Yidan, Saul, Frederick, J\uf6nsson, Friederike, England, Patrick   +35 more
core   +2 more sources

Current recommendations for preventing residual neuromuscular blockade. [PDF]

Anesth Pain Med (Seoul)
Lee JE, Jung H.
europepmc   +1 more source